Literature DB >> 9616266

Distribution of glutaminase and glutamine synthetase activities in the human gastrointestinal tract.

L A James1, P G Lunn, S Middleton, M Elia.   

Abstract

1. The activities of the two key enzymes involved in glutamine metabolism, glutaminase and glutamine synthetase, were measured in mucosal biopsies taken from different sites throughout the human gastrointestinal tract, from oesophagus to rectum. 2. The specific activity of glutamine synthetase was highest in the stomach (4.5 nmol glutamine formed per minute per mg of protein), but both small and large intestine and the oesophagus had little synthesizing capacity (less than 0.3 nmol of glutamine formed per minute per mg of protein). 3. Glutaminase specific activity was highest in the small intestine (53 nmol glutamate formed per minute per mg of protein by duodenal mucosa), intermediate in the large intestine and lowest in the oesophagus and stomach (less than 13 nmol of glutamate formed per minute per mg of protein). 4. The glutamine concentration in the mucosa was lower in the duodenum than in the colon (0.62 and 0.95 mmol/kg wet weight respectively), but both were much lower than the measured K(m) values of glutaminases obtained from these sites (3.8 and 4.0 nmol/kg wet weight respectively). 5. The concentration of glutamine in saliva, stomach juice, bile and duodenal juice suggests that very little glutamine passes into the gastrointestinal tract via these secretions. 6. The study provides the most complete information on the distribution of glutamine synthetase and glutaminase along the human gastrointestinal tract, and suggests that (i) both the small and large intestines have a high potential for glutamine metabolism, but little synthesizing capacity, thus both must derive their glutamine from other sources, and (ii) neither the stomach nor the oesophagus have a high glutaminase activity, although the stomach has substantial capacity to synthesize glutamine. The distribution of the enzymes along the gastrointestinal tract may help rationalize the use of glutamine for treating diseases that affect different parts of the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9616266     DOI: 10.1042/cs0940313

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  8 in total

1.  Potential of magnetic resonance spectroscopy in assessing the effect of fatty acids on inflammatory bowel disease in an animal model.

Authors:  Sonal Varma; Michael N A Eskin; Ranjana Bird; Brion Dolenko; Jayadev Raju; Omkar B Ijare; Tedros Bezabeh
Journal:  Lipids       Date:  2010-08-19       Impact factor: 1.880

2.  Phosphate-activated glutaminase activity is enhanced in brain, intestine and kidneys of rats following portacaval anastomosis.

Authors:  Manuel Romero-Gomez; Maria Jover; Daniel Diaz-Gomez; Laura-Collantes de Teran; Regina Rodrigo; Ines Camacho; Miriam Echevarria; Vicente Felipo; Juan-D Bautista
Journal:  World J Gastroenterol       Date:  2006-04-21       Impact factor: 5.742

Review 3.  Urea cycle disorders-update.

Authors:  Shirou Matsumoto; Johannes Häberle; Jun Kido; Hiroshi Mitsubuchi; Fumio Endo; Kimitoshi Nakamura
Journal:  J Hum Genet       Date:  2019-05-20       Impact factor: 3.172

Review 4.  Role of phosphate-activated glutaminase in the pathogenesis of hepatic encephalopathy.

Authors:  Manuel Romero-Gómez
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.584

Review 5.  Gut ammonia production and its modulation.

Authors:  Manuel Romero-Gómez; María Jover; J Jorge Galán; A Ruiz
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

6.  THDP17 decreases ammonia production through glutaminase inhibition. A new drug for hepatic encephalopathy therapy.

Authors:  M Mar Díaz-Herrero; José A del Campo; Pilar Carbonero-Aguilar; José M Vega-Pérez; Fernando Iglesias-Guerra; Ignacio Periñán; Francisco J Miñano; Juan Bautista; Manuel Romero-Gómez
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

7.  Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation?

Authors:  Bernd Sido; Cornelia Seel; Achim Hochlehnert; Raoul Breitkreutz; Wulf Dröge
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

Review 8.  Is the Response of Tumours Dependent on the Dietary Input of Some Amino Acids or Ratios among Essential and Non-Essential Amino Acids? All That Glitters Is Not Gold.

Authors:  Francesco S Dioguardi; Vincenzo Flati; Giovanni Corsetti; Evasio Pasini; Claudia Romano
Journal:  Int J Mol Sci       Date:  2018-11-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.